Status: Not yet recruiting
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.
Participants needed: 450
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Runshi Pharmaceutical Technology Co., LtdUpdated: Oct 24, 2024
Eligibility criteria
Absolute Neutrophil count (ANC) ≥ 1.5 × 10^9/L; [+6]
1. Patients who have previously received any anti-tumor therapy within 4 weeks p...